Abcam obtains rights to recombinant rabbit MAbs from Roche

22 January 2018

Life science research tool specialist Abcam (AIM: ABC) has signed a licensing deal with Roche (SIX: ROG) that gives the UK company exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of use.

The deal cements Abcam’s position as one of Europe’s biggest biotechs, able to give researchers easy access to the antibodies they need for their work.

Roche acquired Spring, a California-based biotech, in 2007 and the portfolio concerned comprises around 760 products, with the Swiss pharma giant retaining the antibody development capabilities and rights pertaining to the portfolio for internal research, companion diagnostic and IVD uses. Financial terms of the agreement have not been disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK